Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
203.4 USD | +0.34% |
|
-0.52% | -11.05% |
Jun. 17 | Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials | CI |
Jun. 13 | Baird Adjusts Price Target on Laboratory Corp of America Holdings to $258 From $256 | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.05% | 17.09B | B | ||
+19.66% | 83.73B | C+ | ||
-28.23% | 72.21B | B- | ||
-0.35% | 26.2B | C+ | ||
+1.39% | 17.18B | A- | ||
+1.74% | 15.18B | A- | ||
+77.86% | 13.59B | C- | ||
+80.09% | 13.11B | C+ | ||
-22.98% | 12.92B | - | - | |
+20.91% | 12.36B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LH Stock
- Ratings Labcorp Holdings Inc.